Literature DB >> 28195235

Lung cancer: Ceritinib is superior to frontline chemotherapy.

Peter Sidaway.   

Abstract

Entities:  

Year:  2017        PMID： 28195235     DOI： 10.1038/nrclinonc.2017.20

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

Authors:  Jean-Charles Soria; Daniel S W Tan; Rita Chiari; Yi-Long Wu; Luis Paz-Ares; Juergen Wolf; Sarayut L Geater; Sergey Orlov; Diego Cortinovis; Chong-Jen Yu; Maximillian Hochmair; Alexis B Cortot; Chun-Ming Tsai; Denis Moro-Sibilot; Rosario G Campelo; Tracey McCulloch; Paramita Sen; Margaret Dugan; Serafino Pantano; Fabrice Branle; Cristian Massacesi; Gilberto de Castro
Journal:  Lancet       Date:  2017-01-24       Impact factor: 79.321
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.